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Human immunodeficiency virus — one of nature’s
greatest evolutionary machines
Darren Martin and Carolyn Williamson*
From a human perspective, the human immunodeficiency virus
(HIV) story begins around 1930, somewhere in equatorial West
Africa, when it is thought that an obscure chimpanzee virus in-
fected a person.1–3 Unnoticed over the next fifty or so years, this
virus’s descendants spread among people throughout the
world. Even after HIV was discovered in the 1980s, its spread
was relentless, despite intense efforts to stop it. Understanding
this story, and learning from it, is one of the most difficult and
important endeavours that humankind has yet undertaken.
HIV’s ancestors
Long before the first HIV infection of humans, biological
evolution had already produced in HIV’s ancestors the mixture
of features that has made the global AIDS pandemic possible.
These viruses had the potential to evade our defences, integrate
into our genomes, reproduce in our cells and not kill us before
exploiting our sexual habits to move between us.
HIV-like viruses have been discovered in more than twenty
African primate species belonging to two families (apes and
monkeys). Transmission of HIV-like viruses between different
primate species has most likely occurred for many centuries.4
With few exceptions, the HIV-like infections found in their natu-
ral primate hosts are not obviously pathogenic. A degree of toler-
ance (that is, susceptibility without death) may have developed
in, for example, chimpanzees if the virus was introduced from a
different ape species, spread unabated through the chimpanzee
population and killed all susceptible individuals. The small
fraction of chimpanzees that survived infection without devel-
oping an AIDS-like disease would produce offspring that were
themselves tolerant and, in only a few hundred years, infections
would no longer be terminal.
If frequent transmission of HIV-like viruses has occurred
between the different primate species, a reasonable question to
ask is: Why have HIV-like viruses not been transmitted into
humans before? It has, in fact, been determined that besides the
chimpanzee-to-human transmission incident supposedly
around 1930, there have been multiple transmissions of other
HIV-like viruses from primates to humans, resulting in two HIV
types (HIV-1 and -2) and three HIV-1 groups (HIV-1 group M,
group N, and group O).1,3,5 The HIV-1 group M viruses are
responsible for the worldwide AIDS pandemic. Although the
group N and O viruses have much in common with the group M
viruses, they are either not as deadly or have, for some reason,
not spread as successfully.
The virus and its life cycle
Virus particles, otherwise known as virions, are so small they
can be visualized only using electron microscopes. Virions are
Transmission of an HIV-like virus from chimpanzees to humans
approximately 80 years ago triggered the worldwide AIDS pan-
demic. Possessing very high mutation and recombination rates, the
descendants of this ancestral virus have evolved greatly. Most of
this evolution has been in response to selective pressures imposed
by human immune responses and has not provided HIV with any
significant new biological characteristics. The continuing diversifi-
cation of HIV variants is a principal obstruction to controlling the
virus with drugs and vaccines.
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merely the suspended-animation phase of
virus life cycles — analogous to the seed
phase of a flowering plant’s life cycle. At this
stage of its existence, HIV spends its time
being passively transported either between
cells within an infected person or from cells in
an infected person to cells in an uninfected
person. HIV really starts to live only once it
attaches to and enters a cell. HIV, as with all
viruses, depends on its host’s cellular ma-
chinery for survival. The interactions of
viruses with their hosts is especially intimate:
entry of viral particles into host cells involves
‘uncoating’ — the process by which the pro-
tective outer layer(s) of viral particles are
stripped away to expose their genomes
directly to the intracellular environments of
host cells. Viruses in essence become one with
host cells, in many cases (including HIV) even
merging their genomes with those of their
hosts.
Upon infection of a new cell, the HIV’s RNA
genome must be converted to DNA, the form
that integrates into our genome. This process is the reverse of the
normal flow of genetic information and is called reverse tran-
scription (hence the name retrovirus, the family of viruses to
which HIV belongs). To complete one cycle of reproduction, the
DNA must be converted back to RNA, which is then packaged
into the viral particle. All organisms on Earth are capable of
producing RNA copies of a gene (DNA) using a process called
transcription. HIV simply uses the cell’s transcription machinery
to perform this step of its life cycle. Reverse transcription is,
however, not an activity that cells normally perform. HIV must
therefore encode its own reverse transcription machinery.
Genetic economy: compact and complex genomes
There is great selection pressure for viruses to be as small as
possible. Smaller viruses reproduce faster than larger ones and
more of them can fit within an infected cell. The size of any viral
genome is close to the absolute minimum number of nucleotides
required to encode all the things that viruses need to survive. In
stark contrast to our genome, where the overwhelming majority
of nucleotides are apparently superfluous, nearly every nucleo-
tide of HIV’s genome has a purpose.
Virus genomes generally contain only those genes required for
viral reproduction and movement (both from cell to cell within a
host, and between hosts). However, viruses do not encode all the
proteins they need to complete their life cycles — where possi-
ble, they use proteins encoded by their hosts. Virus genomes are
thus a greatly compressed set of instructions required to coerce
their hosts into performing tasks that are necessary for the
virus’s survival.
The complexity of these instructions and the amount of encod-
ing they require reflect both the complexity of a virus species’
life cycle and the harshness of the niche it has evolved to
fill. Whereas HIV has an approximate genome size of ~10 000
nucleotides, the simplest mammalian viruses have genomes of
only ~2000 nucleotides. HIV is five times larger than the small-
est mammalian viruses because (1) its mode of reproduction
requires that it encode some enzymes and proteins that have no
suitable human substitutes, and (2) it needs to survive indefi-
nitely our potent immune systems to ensure its eventual trans-
mission to new hosts. As a consequence of immune pressure, the
virus has devoted a large proportion of its genome to producing
proteins that enable the virus to both evade and suppress host
immune systems.
HIV evolution
HIV has a very high mutation rate, which means that it has the
potential to evolve quickly. Just how fast HIV evolves can be
appreciated by comparing its rate of evolution to that of humans.
However, before making this comparison, it is necessary first to
consider how to measure evolution rates.
Determination of evolution rates is complicated as they can-
not, in most cases, be directly measured and are influenced by a
multitude of different factors, mutation rate being only one of
them. In addition, the relative importance of these different
factors may change drastically during the long evolutionary
history of an organism. However, the accurate determination of
human and HIV evolution rates are unnecessary for us to get a
reasonably good impression of just how different the rates of
human and HIV evolution are.
It is possible to use the sequence of nucleotides in the genes, or
even the entire genomes of a group of related organisms, to
produce an evolutionary tree that describes how the organisms
are related to one another. In such a tree, it is important to note,
first, that there is a point along one of the branches that repre-
sents the common ancestor of all the sequences represented by
the tree, and, second, that the tips of branches represent the
sequences used to construct the tree. Given this, the combined
lengths of the tree’s branches from the point representing the
common ancestor to the tips of any particular branch are propor-
tional to the number of nucleotide changes that the ancestral
sequence underwent during the evolution of the sequence rep-
resented by that branch’s tip. The evolutionary trees for Old
World primates (including humans) and HIV are presented in
Fig. 1. You will notice that the human tree is slightly smaller than
the HIV tree. What is so startling about these trees is that,
whereas the human tree represents 130 million years of evolu-
tion, the HIV tree represents only 70 years.
There are a number of reasons why HIV’s rate of evolution is so
much higher than that of humans. Because mutations usually
occur during reproduction, the more frequently an organism
reproduces, the higher its mutation rate will be. Whereas the
generation times of the apes represented in Fig. 1 are at least a
Fig. 1. Comparison of recent primate and group M HIV-1 evolution rates. Evolutionary relationships
between primate gammaglobin genes and full-length HIV genomes are represented here in tree form. The
tips of the trees’ branches represent the various nucleotide sequences used to construct the trees. Names
and branches in grey represent New World Primate and HIV-1 group N sequences included for comparison
purposes. Dots represent possible tree positions of most recent common ancestors of the Old World
primates and group M HIV-1 subtypes. The combined lengths of branches from the point representing the
common ancestor to the tips of any one branch are proportional to the number of nucleotide changes that
the ancestral sequence underwent during the evolution of the sequence represented by that branch tip.
Whereas the primate tree represents 130 million years of evolution, the HIV-1 tree represents 70 years.
few years, with any individual having approximately two off-
spring, the generation time of HIV is approximately 60 hours,
with each individual genome producing thousands of off-
spring.6
Far more significant than the difference in HIV and human
generation times, however, is the accuracy with which their
respective genome-copying machineries operate. Whereas the
human copying machinery makes only one error per 10 billion
nucleotides copied, the copying machinery of HIV can make up
to one error in every 2000 nucleotides copied.7–9 Unlike the
DNA-to-DNA copying enzymes (called DNA polymerases) that
are used during the reproduction of most organisms, the
RNA-to-DNA copying enzymes (reverse transcriptases) that
are found in retroviruses such as HIV can neither ‘proofread’
their copying efforts nor correct any of the mistakes that they
make. The HIV reverse transcriptase is, however, also particu-
larly error-prone, so that even when compared with other retro-
viruses, HIV has an astonishingly high mutation rate.
HIV-1: the super-mutator
In certain instances, HIV’s mutation rate can be so high that
nearly every new genome that is produced will contain one or
more copying errors. As a consequence, within an infected indi-
vidual it would be very difficult to find any two viruses that were
identical. This assemblage of unique individual mutants is some-
times called a quasi-species. The diversity of different HIV
genomes found within a single AIDS patient can far exceed the
diversity in entire species of higher organisms (including
humans). By infecting individuals with a diverse swarm of
mutant viruses, HIV has unique biological and evolutionary
advantages over disease-causing organisms such as bacteria and
many other viruses that produce infections with genetically
uniform populations. Among these advantages is the ability to
adapt rapidly to hostile host immune systems and antiretroviral
drugs.
The extent of HIV diversity challenges our concept of what
constitutes a species. While the diverse population of viruses
found within an infected person might be similar in genetic
depth to, for example, mammalian species such as humans or
lions, the substantially more diverse range of HIVs found world-
wide is similar in genetic depth to entire groups of species such
as, for example, the primates or cats (Fig. 1). In effect, HIV is not a
single species and, as a result, HIVs found worldwide have been
split into nine groupings called subtypes (named A through K,
excluding I and E). HIV is evolving so fast that within a few
decades it will be necessary to split and re-split the existing sub-
type groups just to keep track of the new viruses that will evolve.
HIV’s extremely high mutation rate does, however, present it
with some serious problems: (1) a large proportion of mutations
will be harmful to the virus, (2) potentially useful mutations may
have no immediate value and might be beneficial only in certain
circumstances, and (3) useful mutations will most likely occur in
genomes that contain other mutations that are harmful. The
discovery that HIV had a mutation rate that could result in
copying errors in nearly every new genome produced was
puzzling. It has long been known that there is a maximum muta-
tion rate beyond which no species can survive. If the mutation
rate of a species were to exceed this maximum (approximately
one error per reproductive cycle), the accumulation of harmful
mutations with every reproduction cycle would result in a
progressive and irreversible loss of genetic vitality that would
drive the species to extinction. The mutation rate of HIV was
believed to be over the theoretical maximum and it was surpris-
ing, therefore, that its genome was not experiencing a so-called
mutational meltdown.
It has, however, been discovered that certain features of HIV’s
biology allow it to push the permissible copying error threshold.
The mutation rate of HIV is not solely dependent on how often
its genome copying machinery makes mistakes. During an infec-
tion, HIV produces proteins that influence its mutation rate
through interaction with host enzymes that both increase10 and
decrease11 the prevalence of genome copying errors. Estimates
of actual mutation rates (as opposed to genome copying errors)
have been as low as one mutation per 30 000 nucleotides copied
— that is, one mutation in every three replication cycles.7 The
involvement of multiple host and virus factors means that the
actual HIV mutation rate most likely differs from one infection to
another.
HIV is able to escape the progressive accumulation of what-
ever harmful mutations do occur through a process called
recombination. Recombination refers to the exchange of genetic
material between two or more genomes within the same cell. It
provides the virus with a very powerful mechanism by which
beneficial mutations can be uncoupled from harmful mutations.
Recombination occurs during the RNA-to-DNA copying step
of reproduction, when the reverse transcriptase enzyme will
use two different HIV RNA genomes to produce a single hybrid
DNA genome copy. The recombination rate in HIV is
extraordinarily high and exceeds the mutation rate.12 The two
features of HIV’s biology that encourage recombinational
rearrangement of mutations are, first, the packaging of two
separate genomes into every virus particle and, second, the
frequent infection of individual cells with more than one virus
particle.
HIV-1: the super-evolver?
Given that HIV seems to be one of nature’s greatest mutators, it
is perhaps interesting that the virus has not evolved any really
significant new characteristics since it first began infecting apes
and humans. With the exception of one or two genes, the
genome structure and overall biology of HIV is still remarkably
similar to HIV-like viruses found in apes and monkeys. For
example, none of the HIV-like viruses has yet evolved an aerosol
or insect transmission strategy. The reliance of HIV and HIV-like
viruses on transmission by direct blood-to-blood contact is nota-
bly inefficient and presents the virus with the difficult and
dangerous need to persist within its hosts for long periods. The
phrase ‘soap opera evolution’ has been used to describe HIV’s
apparent lack of evolutionary progression — much happens but
it never seems to go anywhere.
Evolution is, however, all about strategy. HIV’s strategy is not
to be a super-evolver but rather a super-mutator, able to survive
for long periods within humans. Frequent mutation ensures the
virus remains constantly one step ahead of our immune systems.
To combat HIV, our immune systems are absolutely reliant on
the identification of HIV and HIV-infected cells through the
detection of physical features found only in HIV proteins.
Changing these physical features whenever they are detected is
key to the virus’s success. There is an immediate evolutionary
advantage for any virus variant that avoids an immune response
because it does not possess a targeted physical feature. Such
variants will thrive, while others possessing the feature are
destroyed.
HIV has evolved a complex external structure of inaccessible
pits, hidden grooves and elaborate masking structures that act as
camouflage, effectively enabling the virus to hide from our anti-
body-based immune defences.13 A high mutation rate allows the
virus constantly to change this complex external shield, thus
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effectively enabling continued evasion. Large portions of all HIV
proteins, including many vital working parts, are vulnerable to
detection by our cellular-based immune defences and there is
also much pressure for these parts to change. HIV is able contin-
ually to escape cellular immune defences mediated by, for exam-
ple, cytotoxic T lymphocytes, through mutations that alter parts
of the virus recognized by these immune cells. Even though
many of these immune escape mutations slightly compromise
the functionality of the virus’s working parts the need for
immune escape is absolute and damaged escapees easily
out-compete undamaged viruses that are unable to escape.
None (or at best very few) of the immune evasion mutations that
accumulate during the course of a single infection will have any
use when a virus is transmitted to a new host. Therefore,
whereas HIV’s mutation strategy ensures its survival in the
short term, in the long term it creates what is in effect useless
evolutionary ‘noise’.
The consequences of HIV diversity
Ironically, it is precisely this evolutionary noise that presents
the greatest obstacle to both HIV vaccine development and drug
treatment. Vaccines designed against one subtype may not
protect against another subtype. In fact, primate studies have
shown that some experimental vaccines will work only if the
viruses used to construct the vaccines are identical to those with
which vaccinated animals are subsequently infected.14 Clearly, it
is not possible to make vaccines matched to all existing HIV sub-
types and sub-subtypes, let alone vaccines perfectly matched to
every HIV variant that exists — the number of variants is count-
less and is relentlessly growing with every passing hour.
Current vaccine strategies have tried to overcome this problem
by: (1) focusing on regions of the genome that are conserved
between subtypes; (2) making use of pieces of all the least vari-
able parts of the virus that are detectable by our immune
systems; (3) combining the variable parts of different subtypes;
(4) using theoretical ancestral and consensus proteins, which are
more closely related to the proteins of circulating viruses than
the circulating viral proteins are to one another.15,16 These
vaccines are based on the premise that, despite HIV’s extreme
diversity, there are immune-detectable regions of its genome
that cannot significantly change without compromising their
functionality. However, the amount of viral diversity that could
be controlled by an effective vaccine remains unknown.
Also of concern is that a first-generation vaccine may not
completely block infection, and ‘breakthrough infection’ of
vaccinated individuals may result in the eventual emergence
and spread of vaccine escape mutants. Such a scenario is evident
in regions of the world where drug therapy is common, where as
many as 10% of transmitted viruses are resistant to at least one
antiretroviral drug.
Although the human genome is the focus of more intense
study, the HIV genome is the best-understood of any on Earth.
With an approximate size of 10 000 nucleotides, HIV’s genome is
nearly 300 000 times smaller than the human genome. It is small
enough that over 400 full-length genomes have been sequenced,
the function of each of its genes is known, and the three-dimen-
sional structures of most of the proteins encoded by these genes
have been solved. Despite having a better idea about HIV’s inner
workings than we do for any other organism, we still have no
really fundamental understanding of how the virus works. For
example, we are still unable to use our accumulated knowledge
to construct a convincing computational model of what happens
within an HIV-infected human cell, much less accurately predict
the course that an infection will take in a human body. We fortu-
nately do not need to have such an intimate understanding of
how HIV works to beat it – we simply need to know enough
about it to produce drugs that interfere with its working parts
and vaccines that improve our natural defences against it.
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